Clinical Trial Update: Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating Ivonescimab in combination with docetaxel for advanced non-small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Ivonescimab (AK112/SMT112)

Snippet

Sponsor: Akeso | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: RECRUITING